137 related articles for article (PubMed ID: 30633573)
21. SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric
Serafin V; Porcù E; Cortese G; Mariotto E; Veltri G; Bresolin S; Basso G; Accordi B
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817853
[TBL] [Abstract][Full Text] [Related]
22. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
[TBL] [Abstract][Full Text] [Related]
23. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
[TBL] [Abstract][Full Text] [Related]
24. Second-Generation SYK Inhibitor Entospletinib Ameliorates Fully Established Inflammation and Bone Destruction in the Cherubism Mouse Model.
Yoshimoto T; Hayashi T; Kondo T; Kittaka M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2018 Aug; 33(8):1513-1519. PubMed ID: 29669173
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
Soumerai JD; Ni A; Xing G; Huang J; Furman RR; Jones J; Sharman JP; Hallek M; Adewoye AH; Dubowy R; Dreiling L; Zelenetz AD
Leuk Lymphoma; 2019 Jun; 60(6):1438-1446. PubMed ID: 30407886
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Faderl S; Rai K; Gribben J; Byrd JC; Flinn IW; O'Brien S; Sheng S; Esseltine DL; Keating MJ
Cancer; 2006 Sep; 107(5):916-24. PubMed ID: 16832816
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.
Hong DS; Moore K; Patel M; Grant SC; Burris HA; William WN; Jones S; Meric-Bernstam F; Infante J; Golden L; Zhang W; Martinez R; Wijayawardana S; Beckmann R; Lin AB; Eng C; Bendell J
Clin Cancer Res; 2018 Jul; 24(14):3263-3272. PubMed ID: 29643063
[No Abstract] [Full Text] [Related]
28. Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.
Mato AR; Wierda WG; Davids MS; Cheson BD; Coutre SE; Choi M; Furman RR; Heffner L; Barr PM; Eradat H; Ford SM; Zhou L; Verdugo M; Humerickhouse RA; Potluri J; Byrd JC
Haematologica; 2019 Nov; 104(11):2258-2264. PubMed ID: 30923097
[TBL] [Abstract][Full Text] [Related]
29. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
[TBL] [Abstract][Full Text] [Related]
30. Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma.
Brown JR; Davids MS; Rodon J; Abrisqueta P; Kasar SN; Lager J; Jiang J; Egile C; Awan FT
Clin Cancer Res; 2015 Jul; 21(14):3160-9. PubMed ID: 25840972
[TBL] [Abstract][Full Text] [Related]
31. Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature.
Abuelgasim KA; Rehan H; Alsubaie M; Al Atwi N; Al Balwi M; Alshieban S; Almughairi A
J Med Case Rep; 2018 Mar; 12(1):64. PubMed ID: 29524963
[TBL] [Abstract][Full Text] [Related]
32. Scaffold hopping of the SYK inhibitor entospletinib leads to broader targeting of the BCR signalosome.
Jorda R; Krajčovičová S; Králová P; Soural M; Kryštof V
Eur J Med Chem; 2020 Oct; 204():112636. PubMed ID: 32731189
[TBL] [Abstract][Full Text] [Related]
33. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
34. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
Cramer P; von Tresckow J; Bahlo J; Robrecht S; Langerbeins P; Al-Sawaf O; Engelke A; Fink AM; Fischer K; Tausch E; Seiler T; Fischer von Weikersthal L; Hebart H; Kreuzer KA; Böttcher S; Ritgen M; Kneba M; Wendtner CM; Stilgenbauer S; Eichhorst B; Hallek M
Lancet Oncol; 2018 Sep; 19(9):1215-1228. PubMed ID: 30115596
[TBL] [Abstract][Full Text] [Related]
35. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
[TBL] [Abstract][Full Text] [Related]
36. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
Shah A; Mangaonkar A
Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
[TBL] [Abstract][Full Text] [Related]
37. BTK/PD-1 blockade for treatment of Richter's transformation.
Tang PS; Tam CS
Lancet Haematol; 2019 Feb; 6(2):e59-e60. PubMed ID: 30642820
[No Abstract] [Full Text] [Related]
38. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.
Elter T; Gercheva-Kyuchukova L; Pylylpenko H; Robak T; Jaksic B; Rekhtman G; Kyrcz-Krzemień S; Vatutin M; Wu J; Sirard C; Hallek M; Engert A
Lancet Oncol; 2011 Dec; 12(13):1204-13. PubMed ID: 21992852
[TBL] [Abstract][Full Text] [Related]
39. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
Fischer K; Cramer P; Busch R; Stilgenbauer S; Bahlo J; Schweighofer CD; Böttcher S; Staib P; Kiehl M; Eckart MJ; Kranz G; Goede V; Elter T; Bühler A; Winkler D; Kneba M; Döhner H; Eichhorst BF; Hallek M; Wendtner CM
J Clin Oncol; 2011 Sep; 29(26):3559-66. PubMed ID: 21844497
[TBL] [Abstract][Full Text] [Related]
40. Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study.
Chaoui D; Hacini M; Fitoussi O; Karlin L; Arkam Y; Jourdan E; Orfeuvre H; Voillat L; Sanhes L; Leprêtre S; Liu KL; Barry M; Tempescul A; Dilhuydy MS; Chaib A; Slama B; Labourey JL; Benbrahim O; Dreyfus B; Mahé B; Maynadié M; Delmer A; Benkanoun C; Boissard F; Gandon S; Veerabudun K; Choquet S;
Leuk Lymphoma; 2019 Jun; 60(6):1563-1567. PubMed ID: 30624147
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]